Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06799065 · ClinicalTrials.gov registry record · Phase 1
First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Advanced Solid Tumors, sponsored by Accent Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 90
- Enrollment target
- 5
- Study locations
NCT06799065: Recruiting Phase 1 study of Ovarian Cancer and Advanced Solid Tumors, sponsored by Accent Therapeutics.
NCT06799065 is a Phase 1 study of Ovarian Cancer and Advanced Solid Tumors that is actively recruiting participants, run by Accent Therapeutics. The registered enrollment target is 90 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06799065, a Phase 1 study of Ovarian Cancer and Advanced Solid Tumors, is actively recruiting participants, sponsored by Accent Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 90 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
Primary Outcome
Identification of a tolerable and safe dose for expansion cohorts based on dose limiting toxicities
Conditions Studied
Interventions
- DRUG ATX-295
Study Locations (5)
Texas
- MD Anderson Cancer Center - Houston
- NEXT Oncology - San Antonio
Florida
- Florida Cancer Specialists - Sarasota
Tennessee
- SCRI Oncology Partners - Nashville
Virginia
- NEXT Virginia - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2025-03-21 |
| Est. Completion | 2027-08-30 |
| Phase | Phase 1 |
What NCT06799065 shows while recruiting
NCT06799065 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (88% lower).
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which ATX-295 is the first listed.
NCT06799065 lists 5 locations in 4 states (Texas, Florida, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06799065 about?
NCT06799065 is a clinical study titled "First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer". The goal of this study is to identify a safe and tolerated dose of the orally administered KIF18A inhibitor ATX-295. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of ATX-295 in patients with advanced solid tumors and ovarian cancer.
What is the current status of trial NCT06799065?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 90 participants. The study started on 2025-03-21. Estimated completion is 2027-08-30.
What conditions does trial NCT06799065 study?
This clinical trial studies the following conditions: Ovarian Cancer, Advanced Solid Tumors, Triple Negative Breast Cancer, Breast Cancer Recurrent, High-grade Serous Ovarian Carcinoma.
What interventions are being tested in trial NCT06799065?
The interventions under investigation include: ATX-295 (DRUG).
Who is sponsoring clinical trial NCT06799065?
This trial is sponsored by Accent Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06799065 being conducted?
This trial has 5 study locations across Florida, Tennessee, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06799065's enrollment target sits among peer trials
90 156th of 322 higher than 162 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI